Table 4 Signals associated with decreased cancer risk (exposure: any prescription)
Cancer | Adjusted for comorbidities†| Adjusted for comorbidities†and smoking |
|---|---|---|
Breast§ | Trazodone (OR = 0.79) | Trazodone (OR = 0.74) |
Lung | Fluocinolone* (OR = 0.67) Levodopa (OR = 0.50) Nitrofurantoin (OR = 0.74) Progestogen-contraceptive (OR = 0.62)§ Risperidone (OR = 0.55) | Fluocinolone* (OR = 0.66) |
Colorectal | Levodopa (OR = 0.60) Lofepramine (OR = 0.71) Meloxicam (OR = 0.76) Metoclopramide (OR = 0.78) Nitrofurantoin (OR = 0.71) | Metoclopramide (OR = 0.77) Nitrofurantoin (OR = 0.66) |
Prostate§§ | Levodopa (OR = 0.47) Risperidone (OR = 0.37) Senna (OR = 0.76) | Levodopa (OR = 0.44) Risperidone (OR = 0.38) Senna (OR = 0.77) |
Bladder | Iron (OR = 0.77) | Sotalol (OR = 0.19) |
Malignant melanoma | Dipyridamole (OR = 0.42) Gliclazide (OR = 0.51) | Gliclazide (OR = 0.49) |
Oesophagus | Estrogen-HRT (OR = 0.59)§ | Diazepam (OR = 0.73) Estrogen-HRT (OR = 0.61)§ |
Non-Hodgkin’s lymphoma | Progestogen-contraceptive (OR = 0.56)§ | Progestogen-contraceptive (OR = 0.49)§ |
Oral (inc. head, neck, nasal) | Doxycycline (OR = 0.45) Ispaghula (OR = 0.63) | Doxycycline (OR = 0.43) |
Ovary§ | Loratadine (OR = 0.64) Progestogen-contraceptive (OR = 0.55) | Progestogen-contraceptive (OR = 0.56) |
Cervix and other gynae§ | Terbinafine (OR = 0.18) | Terbinafine (OR = 0.20) |
Uterus§ | Estrogen-HRT (OR = 0.73) Progestogen-contraceptive (OR = 0.37) | Progestogen-contraceptive (OR = 0.37) |
Larynx | Doxazosin (OR = 0.36) Terbinafine (OR = 0.32) | – |